nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-4D45AC05·Framework v5.0·Pipeline v0.4·Evaluated 14 Jun 2026·OECD: 3.2 Clinical medicine·Subfield: Genetics·Basis: Full text·Type: Observational cohort study

The efficacy of curcumin/Qing Dai combination in children with active ulcerative colitis: a multicenter retrospective cohort study.

Nachum et al.Nachum, Salomon, Yerushalmy-Feler et al.·2024·Frontiers in pediatrics·10.3389/fped.2024.1342656 ↗

In brief

A first multicenter pediatric cohort offering hypothesis-generating evidence for CurQD in active ulcerative colitis, constrained by an uncontrolled design that cannot separate the herbal effect from concomitant therapy.

ReliabilityCaveats3 of 4 checks completeRead the 2 entries ↓
Abstract

BACKGROUND: Curcumin and Qing Dai (QD) are herbal extracts that recently showed efficacy in treating inflammatory bowel disease (IBD). Since 2016, a combination of curcumin with QD (CurQD) has been employed in our center for management of active ulcerative colitis (UC).

OBJECTIVES: We report the effectiveness and safety of CurQD therapy in children with mild-moderate UC or IBD-unclassified (IBD-U).

DESIGN: A multicenter retrospective study.

METHODS: Children aged ≤OP18 years who were treated with CurQD during 2017-2021 were included. Disease activity measures were Pediatric UC Activity Index (PUCAI), and fecal calprotectin (FC). The primary outcome was a decrease in PUCAI by ≥10 points, FC normalization (≤100 µg/gr when baseline ≥300 µg/gr) or a ≥ 50% decrease in FC.

RESULTS: Of 30 patients (60% males, mean age 14 ± 3.9 years), 15 (50%), 13 (43%), and 2 (7%) had pancolitis, left-sided colitis and proctitis, respectively. The daily medication dose was 0.5-3 gm QD with 1-4 gm curcumin. Concomitant treatment at induction was corticosteroids (19%), biologics (28%) and 5-aminosalicylic acid (40%). The mean duration of induction was 11.6 weeks [95% confidence interval (CI) 10.2-13.1, range 8-16]. PUCAI decreased from a mean of 31.3 (95% CI 26.6-36.0, range 5-60) to 10.9 (95% CI 7.6-14.4, range 5-35) (n = 26, p < 0.001). FC response and normalization occurred in 11/12 and 7/12 patients, respectively. The median decline in FC was from 749 µg/gm [interquartile range (IQR) 566-1000] to 39 µg/gm (IQR 12-132) (n = 15, p = 0.04). During follow-up (median 8 months, IQR 6-10), 10 patients (33%) flared; five of them regained remission or responded to a treatment change. Of 18 patients treated beyond induction, 12 (67%) achieved clinical response and 10 achieved clinical remission by the end of follow up.

CONCLUSION: CurQD may be effective and safe as an add-on option to conventional management, for induction and maintenance in children with mild-moderate UC/IBD-U.

Strengths · Limitations

Strengths

#contribution

First multicenter pediatric CurQD cohort

The study addresses a genuine evidence gap by reporting curcumin/Qing Dai combination therapy in children with active UC/IBD-U across four centers, extending adult trial evidence into an understudied pediatric add-on setting.

↳ Introduction; Results, Patients and Management

#application pathway

Real-world clinical setting and follow-up

The multicenter design with both induction and prolonged maintenance follow-up reflects real-world clinical use, supporting relevance to pediatric gastroenterologists considering adjunctive options in refractory disease.

↳ Results, Efficacy of Maintenance; Discussion

#positioning

Candid disclosure of study limitations

The discussion openly acknowledges the retrospective design, missing data, ascertainment bias from endoscopy performed mainly in non-responders, and possible under-detection of pulmonary hypertension because echocardiograms were not routine.

↳ Discussion, limitations paragraphs

Limitations

#methodological rigour

Uncontrolled confounding from concurrent therapy

Most patients were on concurrent 5-ASA (63%), biologics (30%), or corticosteroids (20%) at induction, with no control group and no adjustment or stratification, so observed improvement cannot be attributed specifically to CurQD.

↳ Results, Patients and Management; Methods

#methodological rigour

Substantial and selective missing outcome data

Paired fecal calprotectin was available for only 12-15 of 30 patients and post-induction PUCAI was missing for four, with missingness treated as non-available without sensitivity analysis and endoscopy performed predominantly in non-responders.

↳ Results, Efficacy of Induction; Methods, Statistical Analysis

#reporting

Internal inconsistencies and absent disclosures

Concomitant-medication percentages and flare counts differ between abstract and full text, the statistical description conflates parametric and nonparametric summaries, and no conflict-of-interest statement accompanies a study of a named commercial product.

↳ Abstract vs. Results; Methods, Statistical Analysis; Management Regimen

Does this match your read? Add your assessment ↓

Nabu Commentary

The adjudicated scores are driven primarily by the tension between a genuinely novel pediatric contribution and an observational design that cannot isolate the treatment effect. Because the majority of patients received concurrent 5-ASA, biologics, or corticosteroids and no adjustment was attempted, the observed PUCAI and fecal calprotectin improvements cannot be attributed specifically to CurQD, which holds Methodological Rigour below the midpoint. Outcome data are materially incomplete, with paired calprotectin available for only a minority and endoscopy concentrated in non-responders, compounding the inferential limits. The combined primary outcome reported as separate components and the inconsistencies between abstract and full text reduce precision, while the candid limitations section and clear structure support the higher Reporting and Positioning scores. Impact potential is moderate and clearly separated from quality: the work is well-positioned as a stepping stone toward a prospective pediatric trial but is too preliminary to inform practice on its own.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.7±0.1

Contribution
2.8

The score reflects a genuine but preliminary advance: the first multicenter report of CurQD in pediatric UC/IBD-U, addressing a sparse-evidence area with appropriately hedged conclusions. The contribution is limited by the uncontrolled retrospective design and small sample, which prevent isolating the combination's specific added value.

Introduction; Conclusion

data on curcumin or QD treatment in pediatric UC are scarce

Methodological Rigour
2.5

The score reflects a reasonable observational design undermined by uncontrolled confounding, with 63% of patients on 5-ASA, 30% on biologics, and 20% on corticosteroids at induction and no adjustment or stratification. Substantial missingness (PUCAI missing for 4/30, paired FC for only 12-15/30) handled as 'non-available' without sensitivity analysis, selective endoscopic follow-up in non-responders, and imprecise statistical reporting further limit inference.

Results, Patients and Management; Methods, Statistical Analysis; Discussion limitations

endoscopic follow-up was performed predominantly in non-responding patients

Reporting
3.2

The score reflects a well-structured paper with clear tables and figures and a logical flow, reduced by inconsistencies between abstract and full text and by a combined primary outcome that is reported as separate components without a clear combined response rate.

Methods, Outcome; Abstract vs. Results

a decrease in PUCAI by at least 10 points, and reduction in FC levels by 50%

Positioning
3.1

The score reflects solid engagement with relevant adult and pediatric QD/curcumin literature and a candid limitations section, offset by thin treatment of the central confounding problem, no engagement with broader pediatric adjunct-therapy options, and no reporting-guideline framing.

Introduction; Discussion limitations

the study has limitations stemming from the small sample size and the retrospective design

Lower confidence on Positioning — domain match limited.

Reliability

Caveats3 of 4 checks


Internal CoherenceNoted

Several reporting inconsistencies between abstract and full text affect interpretation of exact response estimates but do not reverse core findings. The combined primary outcome is reported as separate components, and the statistical methods description is imprecise.

Research ConductNoted

Ethics approval is declared with an identifier but unverifiable from the paper. No conflict of interest statement is present despite a named commercial manufacturer of the study product, and data availability is restricted to request without a repository.

Flags: 2 declared / 5 total

Reference IntegrityPending

Not yet checked.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Oral and gastrointestinal · Inflammatory bowel disease
Type of advanceEmpirical
Route to useNamed
AdvanceExtends
BeneficiariesSmall
CitationsFWCI 3.0
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

A small retrospective multicenter cohort of 30 children without a control group shows proof of concept, not independent or controlled confirmation.

From the paper
“CurQD might be an effective and safe management for pediatric patients with mild to moderate UC who failed conventional management.”

The conclusion names a concrete clinical use, an add-on management for a defined patient population, that pediatric gastroenterologists would apply in practice.

Pathway

Pediatric gastroenterologists could use CurQD as an add-on induction and maintenance therapy for children with mild-moderate UC, pending confirmatory prospective trials.

Barrier

The evidence is a small, uncontrolled, retrospective cohort with missing outcome data, so larger prospective controlled trials are needed before clinical adoption.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. The regulatory role of Nrf2 in antioxidants phase2 enzymes and IL-17A expression in patients with ulcerative colitis

    Milad Sabzevary-Ghahfarokhi, Mojtaba Shohan, Hedayatollah Shirzad, et al. · 2018 · Basic medicine

    Primary claim

    Oxidative stress in inflamed colonic tissue can induce Nrf2 gene expression. The performance of Nrf2 transcription factor may lead to the induction of GST-A4 and PRDX1.

    Unsupported
    Evidence Score
    2.3±0.1
    Reliability
    Caveats
  2. Curcumin for maintenance of remission in ulcerative colitis

    Kumar, Ahuja, Sankar, et al. · 2012 · Clinical medicine

    Evidence Score
    3.8±0.1
    Reliability
    Caveats
  3. The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials

    Coelho, Romi, Ferreira, et al. · 2020 · Clinical medicine

    Evidence Score
    3.1±0.1
    Reliability
    Caveats

How the rubric works →